Sponsor have decided to cancel the trial

This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.

This is a Phase 1, randomized, double-blind, placebo-controlled, sequential single/repeated-dose study. This study is a dose-escalation study with healthy participants in single ascending dose (SAD) including food-effect and multiple ascending dose (MAD) cohorts to determine the highest allowable dose (HAD).

Inclusion Criteria:

• Must be Caucasian (White American of European or Latin American descent).
• Healthy participants of Japanese origin are allowed up to 50% in each MAD cohort.
• Body mass index (BMI) within the range of 18.5 to 30 kg/m^2 (inclusive) at the time of Screening.
• No congenital or chronic diseases that require treatment and without pathologic symptoms or signs on medical examinations.
• Participants with normal renal function.
• Women are eligible to participate if not pregnant, not breastfeeding. Male subjects should be willing to use 'highly effective' or 'applicable' contraceptive methods.

Exclusion Criteria:

• Currently have an acute disease with active symptoms.
• History of melanoma or other skin issues (including, but not limited to pre-cancerous areas, atopic dermatitis, psoriasis, rosacea, excessive moles etc.).
• History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, musculoskeletal, or cardiovascular disease and/or arrhythmias.
• History of clinically significant hypersensitivity reaction to any drugs or additives.
• History of any gastrointestinal disease.
• History of substance use disorder including history of drug abuse disorder or history of alcohol use disorder, or tobacco use disorder or excessive caffeine intake.
• Evidence of moderate or excessive alcohol consumption.
• Tested positive in viral serology tests (hepatitis B virus [HBV], hepatitis C virus [HCV], and human immunodeficiency virus [HIV]).
• Known family history or known presence of long QT syndrome.
• A history of hypokalemia.
• Use of concomitant medicines that prolong QT/QTc (QT Interval Corrected for Heart Rate).
• History of active viral hepatitis (hepatitis A, B, C, and E), or autoimmune hepatitis.
• History of Multiple Endocrine Neoplasia type 2.
• Solid organ transplantation, except corneal transplants.
• History or presence of neutropenia which is defined as absolute neutrophil count (ANC) < 1.5 at Screening and admission.
• Participants with a microalbuminuria.
• Hemoglobin levels below 12.0 g/dL at Screening or Baseline.
• White Blood Cell levels below 3.5 × 109/L at Screening or Baseline.
• Platelet count < 150,000/µL, international normalized ratio (INR) > 1.5, albumin < 3.5 g/dL